Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2022 / Cilt: 28 - Sayı: 1

The Impact of p53 and Ki67 Expression in Endometrial Cancer and its Effect on Survival

Sayfa
82–88
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: This study was conducted to evaluate the relationship of p53 and Ki67 expression with prognostic factors in patients who underwent surgery due to a diagnosis of endometrial cancer, and to evaluate their use as molecular markers that can help with survival prediction.
📊
Temel Bulgular & Veri:STUDY DESIGN: This retrospective cohort study included patients who underwent surgery for endometrial cancer indication at the Gynecologic Oncology Clinic of the University of Health Sciences Tepecik Training and Research Hospital between 2011 and 2019, and whose p53 and Ki67 from the dissected material were pathologically studied and who underwent pelvic/paraaortic lymph dissection between the relevant dates.
💡
Sonuç & Katkı:Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2011 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: This study was conducted to evaluate the relationship of p53 and Ki67 expression with prognostic factors in patients who underwent surgery due to a diagnosis of endometrial cancer, and to evaluate their use as molecular markers that can help with survival prediction. STUDY DESIGN: This retrospective cohort study included patients who underwent surgery for endometrial cancer indication at the Gynecologic Oncology Clinic of the University of Health Sciences Tepecik Training and Research Hospital between 2011 and 2019, and whose p53 and Ki67 from the dissected material were pathologically studied and who underwent pelvic/paraaortic lymph dissection between the relevant dates. RESULTS: The study included 140 patients who met the inclusion criteria, 60% (n=84) of whom had endometrioid type endometrial carcinoma and 40% (n=56) had non-endometrioid type endometrial carcinoma. Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p

🔖

Bu Makaleye Atıf Yap

KARADENIZ, T., SANCI, M., BAYRAKTAR, B., SAHIN, Z. (2022). The Impact of p53 and Ki67 Expression in Endometrial Cancer and its Effect on Survival. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 28 - Sayı: 1, 82–88. https://ajindex.com/articles/525809

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Colombo N, Creutzberg C, Amant F, Bosse T, GonzálezMartín A, Ledermann J, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41. Doi: 10.1093/annonc/ mdv484. Erratum in: Ann Oncol. 2017;28(suppl 4): iv167-iv168
  2. Carlson JW, Kauderer J, Hutson A, Carter J, Armer J, Lockwood S, et al. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol. 2020;156(2): 467-74. Doi: 10.1016/j.ygyno.2019.10.009
  3. Ghezzi F, Uccella S, Cromi A, Bogani G, Robba C, Serati M, Bolis P. Lymphoceles, lymphorrhea, and lymphedema after laparoscopic and open endometrial cancer staging. Ann Surg Oncol. 2012;19(1):259-67. Doi: 10.1245/ s10434-011-1854-5
  4. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017;10(10): CD007585. Doi: 10.1002/14651858.CD007585.pub4
  5. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16. Doi: 10.1093/jnci/djn 397
  6. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017;10(10): CD007585. Doi: 10.1002/14651858.CD007585.pub4
  7. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403-12. Doi: 10.1182/blood-2012-09-458265
  8. Kreipe H, Ki67-Tumorheterogenität vs. Assayhetero - genität [Ki67: biological intertumor variance versus variance of assay]. Pathologe. 2018;39(Suppl 2):272-77. Doi: 10.1007/s00292-018-0502-2
  9. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105(2):109. Doi: 10.1016/j.ijgo.2009.02.010
  10. Kurman RJ, Carcangiu ML, Herrington S, Young RH. Tumours of the Female Reproductive Organs. WHO classification of tumours. Lyon: IARC Press; 2014
  11. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7. Doi: 10.1016/ 0090-8258(83)90111-7
  12. Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of